Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Casetelnau le Lez, France Clinical Trials

A listing of Casetelnau le Lez, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (17) clinical trials

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Regorafenib (BAY 73-4506) was assessed in metastatic colorectal cancer in the phase III randomized CORRECT trial. 760 metastatic colorectal cancer patients were recruited after the failure of all standard therapies. Given the promising efficacy and favorable tolerability profile of mGEMOX and the potential benefits of targeting the VEGF and Ras/Raf ...

Phase

1.85 miles

Learn More »

Trial of Taselisib in Overgrowth

Segmental overgrowth disorders are rare conditions characterised by abnormal growth which is usually asymmetric and confined to discrete parts of the body. We and others have identified mosaic activating mutations in the p110 catalytic subunit of phosphatidylinositol-3-kinase (PI3K; encoded by the PIK3CA gene) in a subset of overgrowth disorders. The ...

Phase

1.85 miles

Learn More »

Open-Label Multicenter Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL

This is a multicenter, open-label, Phase 1/2 study that is being conducted in two parts. The Phase 1 part (closed to accrual as of January 25, 2016) is comprised of dose escalation and expansion parts to establish the MTD and/or the recommended Phase 2 dose (RP2D) when tazemetostat is given ...

Phase

1.85 miles

Learn More »

Fluorouracil Cisplatin Cetuximab and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - To determine the maximum tolerated dose of fluorouracil and cisplatin when administered with cetuximab concurrently with esophageal radiotherapy. (Phase I) - To determine the complete histological response rate (after surgical resection). (Phase II) Secondary - To determine progression-free survival and overall survival. (Phase II) - To determine ...

Phase

1.85 miles

Learn More »

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). Patients with advanced cancer are eligible if ...

Phase

1.85 miles

Learn More »

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will ...

Phase

1.85 miles

Learn More »

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a ...

Phase

1.85 miles

Learn More »

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Comparative interventional prospective phase 2, randomised, open-label, multicentric trial comparing the combination of regorafenib and irinotecan (REGIRI) to irinotecan alone (IRI) as second line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.

Phase

1.85 miles

Learn More »

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate ...

Phase

1.85 miles

Learn More »

Safety Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

Colorectal cancer (CRC) is a major cause of morbidity and mortality globally. More than 50% of patients can be expected to develop metastatic disease, and most of these patients will require palliative systemic therapy. The primary goal for patients who present with technically resectable liver metastases is definitely cure, with ...

Phase

1.85 miles

Learn More »